ICAR GUIDELINES Bundle (free trial)

Rhinology and Allergy Rhinosinusitis

ICAR IFAR GUIDELINES brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512430

Contents of this Issue

Navigation

Page 8 of 27

9 Cost Benefit-Harm Assessment Policy Level Low Preponderance of benefit over harm Recommendation: Saline irrigation improves symptoms, QoL and nasal endoscopy. Duration should be >8 weeks. Hypertonic saline is more effective but may be more irritating than isotonic saline. ere is no advantage of heated over room temperature saline. Devices with volume >60 mL bring greater benefits Low Preponderance of benefit over harm with short-term treatment with follow-up Strong recommendation: For short-term management of CRSwNP. Longer term use is not supported by the literature and carries increased risk of harm Low to Moderate Possible mild benefit over harm Option: Standard metered dose INCS could be used in treatment of CRSsNP, particularly if primary symptoms are that of rhinitis Low to Moderate Benefit outweighs harm Strong recommendation: INCS are recommended for CRSwNP before or aer sinus surgery. Consideration for twice daily dosing if initial treatment effect is small Moderate to High Preponderance of benefit over harm, with increased cost compared to nasal sprays Recommended: Post-operative patients Option: Non-surgical/medical management Moderate Benefit outweighs harm compared with oral corticosteroids but caution in patients on multiple topical therapies If not controlled with INCS, strong recommendation for corticosteroid irrigation; recommendation for atomization/nebulization. Option: Exhalation delivery

Articles in this issue

view archives of ICAR GUIDELINES Bundle (free trial) - Rhinology and Allergy Rhinosinusitis